The US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Nuvo Research's Pliaglis (lidocaine/tetracaine) 7%/7% cream.
Pliaglis, a topical local anesthetic cream forms a pliable peel on the skin and is used on skin of adults to provide local analgesia for superficial aesthetic procedures, such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing and laser-assisted tattoo removal.
Nuvo has licensed global marketing rights for Pliaglis to Galderma, a global pharmaceutical company specialised in dermatology.
Galderma Laboratories US and Canadian operations president Francois Fournier said, "Pliaglis offers a pre-treatment solution and contributes to improving the patient experience of an aesthetic treatment."
Nuvo Pain Group president Bradley Galer said, "Pliaglis is an important part of Nuvo's expanded topical pain product portfolio."
